Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05486390
Other study ID # 202203-00046
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 17, 2023
Est. completion date May 2025

Study information

Verified date April 2024
Source Singapore General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic diseases are the leading cause of deaths in Singapore. The rising prevalence in chronic diseases with age and Singapore's rapidly aging population calls for new models of care to effectively prevent the onset and delay the progression of these diseases. Advancement in medical technology has offered new innovations that aid healthcare systems in coping with the rapid rising in healthcare needs. These include mobile applications, wearable technologies and machine learning-derived personalized behaviorial interventions. The overall goal of the project is to improve health outcomes in chronic disease patients through delivering targeted nudges via mobile application and wearable to sustain behavioral change. Our overall objective is to design, develop, and evaluate an adaptive intervention platform on wearable devices and shared decision-making during consultations for patients with diabetes and hypertension. Our aim for this study is to assess the clinical effectiveness of real-time personalized educational and behavioural interventions delivered through wearable (Fitbit) and an integrative mobile application in improving patient glycaemic control measured using HbA1c over 9 months. Secondary outcomes will include change in systolic blood pressure, quality of life (QoL), patient activation, medication adherence, physical activity level, diet, direct healthcare cost and indirect healthcare cost over 9 months. We will conduct a randomized controlled trial among patients with comorbid diabetes and hypertension. This proposal aims to develop sustainable and cost-effective behavioural change among patients with comorbid diabetes and hypertension through patient empowerment and targeted chronic disease care.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 320
Est. completion date May 2025
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 21 Years to 100 Years
Eligibility Inclusion Criteria: 1. Aged 21 years old and above 2. Have been diagnosed with diabetes at time of recruitment 3. Most recent glycated haemoglobin (HbA1c) = 7.0% 4. Systolic blood pressure= 140 mmHg or diastolic blood pressure = 90 mmHg on two or more prior visits, physician-diagnosed hypertension, or on antihypertensive medication 5. Physically able to exercise 6. Literate in English 7. Agreeable to be monitored by EMPOWER and/or Fitbit apps 8. Able to conform to monitoring schedule Exclusion Criteria: 1. On bolus insulin treatment 2. Require assistance with basic activities of daily living (BADL) 3. Have planned major operation or surgical procedure within next 9 months 4. Cognitively impaired (scored = 6 on the Abbreviated Mental Test)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Nudge, health coaching and shared decision-making
The EMPOWER app aims to nudge the participant towards successful self-management of their diabetes condition by encouraging and reinforcing positive lifestyle behaviors in 3 main aspects - diet, physical activity, medication adherence. Notifications included content based on behavioural change technique including feedback on performance, positive reinforcement, and prompts to self-monitor. Each notification focused on a single behaviour (physical activity, medication adherence or diet). The participants in the intervention group will also interact with health coach throughout the study duration. In this study, the health coach will be responsible for the following roles : Goal setting and action plan After-visit summary A report card summarizing the lifestyle behaviour, goals will be made available to facilitate shared decision making.

Locations

Country Name City State
Singapore SingHealth Polyclinic (Bedok) Singapore
Singapore SingHealth Polyclinic (Punggol) Singapore
Singapore SingHealth Polyclinic (Tampines) Singapore

Sponsors (4)

Lead Sponsor Collaborator
Singapore General Hospital Duke-NUS Graduate Medical School, National University of Singapore, SingHealth Polyclinics

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary HbA1c HbA1c over 9 months 9 months
Secondary Systolic blood pressure Systolic blood pressure over 9 months 9 months
Secondary Physical activity as measured by number of steps Physical activity over 9 months 9 months
Secondary Physical activity as measured by moderate to vigorous active minutes Physical activity over 9 months 9 months
Secondary Patient activation score as measured by patient activation measure Difference in patient activation score between intervention and control over 9 months 9 months
Secondary Medication adherence as measured by Voils Scale Difference in medication adherence between intervention and control over 9 months 9 months
Secondary Quality of life as measured by EQ-5D-5L Difference in quality of life between intervention and control over 9 months 9 months
Secondary Healthcare cost Healthcare cost over 9 months 9 months
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A